Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases

Oncogene volume 19, pages 2846–2854 (2000)Cite this article

Abstract

The c-myb proto-oncogene encodes a nuclear phosphoprotein that plays a crucial role in normal hematopoiesis. It is a short-lived transcription factor rapidly degraded by the 26S proteasome. Although it has been shown that instability determinants reside in its carboxyl terminus, the molecular mechanism of c-Myb degradation is unknown. Here, we report the first evidence that phosphorylation plays a role in targeting the protein to the proteasome. Inhibition of cellular serine/threonine protein phosphatase activity by okadaic acid resulted in hyperphosphorylation of c-Myb and extremely rapid turnover. The hyperphosphorylation resulted in a protein with altered properties that was indicative of conformational changes. Its mobility on gel electrophoresis was altered as well as its recognition by specific monoclonal antibody. The altered hyperphosphorylated protein still bound to DNA with an affinity similar to that of the hypophosphorylated form. Phosphorylation of three previously identified sites, serines 11, 12, and 528, does not appear to be involved in the proposed changes in conformation or stability. However, phosphoamino acid analyses of the hyperphosphorylated form of c-Myb revealed increased c-Myb phosphorylation mainly on threonine residues that correlated with other okadaic acid-induced alterations of c-Myb. These findings indicate that Ser/Thr phosphatases prevent conformational changes that may play an important role in controlled degradation of c-Myb.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Aziz N, Wu J, Dubendorff JW, Lipsick JS, Sturgill TW and Bender TP . 1993 Oncogene 8: 2259–2265

  • Aziz N, Miglarese MR, Hendrickson RC, Shabanowitz J, Sturgill TW, Hunt DF and Bender TP . 1995 Proc Natl Acad Sci USA 92: 6429–6433

  • Bading H, Beutler C and Moelling K . 1989 Oncogene 4: 33–38

  • Bender TP and Kuehl MW . 1986 Proc Natl Acad Sci USA 83: 3204–3208

  • Biedenkapp H, Borgmeyer U, Sippel AE and Klempnauer KH . 1988 Nature 335: 835–837

  • Bies J and Wolff L . 1997 Oncogene 14: 203–212

  • Bies J, Hoffman B, Amanullah A, Giese T and Wolff L . 1996 Oncogene 12: 355–363

  • Bies J, Nazarov V and Wolff L . 1999 J Virol 73: 2038–2044

  • Biesova Z, Piccoli C and Wong WT . 1997 Oncogene 14: 233–241

  • Brown K, Gerstberger S, Carlson L, Franzoso G and Sienbenlist U . 1995 Science 267: 1485–1487

  • Calkhoven CF and Ab G . 1996 Biochem J 317: 329–342

  • Chen ZJ, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D and Maniatis T . 1995 Genes Dev 9: 1586–1597

  • Dai P, Akimaru H, Tanaka Y, Hou DX, Yasukawa T, Kanei-Ishii C, Takahashi T and Ishii S . 1996 Genes Dev 10: 28–40

  • Dash AB, Orrico FC and Ness SA . 1996 Genes Dev 10: 1858–1869

  • Diehl JA, Zindy F and Sherr CJ . 1997 Genes Dev 11: 957–972

  • Dubendorff JW and Lipsick JS . 1999 Oncogene 18: 3452–3460

  • Grasser FA, Graf T and Lipsick JS . 1991 Mol Cell Biol 11: 3987–3996

  • Howe KM and Watson RJ . 1991 Nucl Acids Res 19: 3913–3919

  • Howe KM, Reakes CFL and Watson RJ . 1990 EMBO J 9: 161–169

  • Hu YL, Ramsay RG, Kanei-Ishii C, Ishii S and Gonda TJ . 1991 Oncogene 6: 1549–1553

  • Ibanez CE and Lipsick JS . 1990 Mol Cell Biol 10: 2285–2293

  • Kalkbrenner F, Guehmann S and Moelling K . 1990 Oncogene 5: 657–661

  • Kanei-Ishii C, MacMillan EM, Nomura T, Sarai A, Ramsay RG, Aimoto S, Ishii S and Gonda TJ . 1992 Proc Natl Acad Sci USA 89: 3088–3092

  • Klempnauer KH and Sippel AE . 1987 EMBO J 6: 2719–2725

  • Koepp DM, Harper JW and Elledge SJ . 1999 Cell 97: 431–434

  • Krieg J, Oelgeschlager M, Janknecht R and Luscher B . 1995 Oncogene 10: 2221–2228

  • Laney JD and Hochstrasser M . 1999 Cell 97: 427–430

  • Liebermann DA and Hoffman-Liebermann B . 1989 Oncogene 4: 583–592

  • Luscher B and Eisenman RN . 1992 J Cell Biol 118: 775–784

  • Luscher B, Christenson E, Litchfield DW, Krebs EG and Eisenman RN . 1990 Nature 344: 517–522

  • Miglarese MR, Richardson AF, Aziz N and Bender TP . 1996 J Biol Chem 271: 22697–22705

  • Ness SA . 1996 Biochem Biophys Acta 1288: F123–F139

  • Ness SA, Marknell A and Graf T . 1989 Cell 59: 1115–1125

  • Nishina Y, Nakagoshi H, Imamoto F, Gonda TJ and Ishii S . 1989 Nucleic Acids Res 17: 107–117

  • Ogata K, Kanei-Ishii C, Sasaki M, Hatanaka H, Nagado A, Enari M, Nakamura H, Nishimura Y, Ishii S and Sarai A . 1996 Nat Struct Biol 2: 178–187

  • Oelgeschlager M, Janknecht R, Krieg J, Schreek S and Luscher B . 1996 EMBO J 15: 2771–2780

  • Oelgeschlager M, Krieg J, Luscher-Firzlaff JM and Luscher B . 1995 Mol Cell Biol 15: 5966–5974

  • Sakura H, Kanei-Ishii C, Nagase T, Nakagoshi H, Gonda TJ and Ishii S . 1989 Proc Natl Acad Sci USA 86: 5758–5762

  • Tavner FJ, Simpson R, Tashiro S, Favier D, Jenkins NA, Gilbert DJ, Copeland NG, Macmillan EM, Lutwyche J, Keough RA, Ishii S and Gonda TJ . 1998 Mol Cell Biol 18: 989–1002

  • Vlach J, Hennecke S and Amati B . 1997 EMBO J 16: 5334–5344

  • Weston K . 1998 Curr Opin Genet Dev 8: 76–81

  • Weston K and Bishop JM . 1989 Cell 58: 85–93

  • Wolff L . 1996 Crit Rev Oncog 7: 245–260

  • Won KA and Reed SI . 1996 EMBO J 15: 182–193

Download references

Acknowledgements

We thank TP Bender and MR Miglarese for providing vector containing mutant FL-Myb(S528A) and B Luscher for providing vector containing mutant FL-Myb(S11,12A). This work was supported in part by a grant No. 2/5052/98 from VEGA Slovak Academy of Sciences.

Author information

Authors and Affiliations

  1. Laboratory of Molecular Virology, Cancer Research Institute, Slovak Academy of Sciences, Bratislava, 833 92, Slovakia

    Juraj Bies & Sona Feiková

  2. Laboratory of Cellular Oncology, National Cancer Institute, NIH, Bethesda, 20892-4255, Maryland, MD, USA

    Juraj Bies, Sona Feiková & Linda Wolff

  3. Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH, Bethesda, 20892-4255, Maryland, MD, USA

    Donald P Bottaro

Authors
  1. Juraj Bies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sona Feiková
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Donald P Bottaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Linda Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bies, J., Feiková, S., Bottaro, D. et al. Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases. Oncogene 19, 2846–2854 (2000). https://doi.org/10.1038/sj.onc.1203613

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203613

Keywords

This article is cited by

Search

Advanced search

Quick links